4p004

Phase 2

44Moving Biotech

4p004 is one of 14 therapeutic programs targeting Knee Osteoarthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Knee OsteoarthritisActive, not recruiting

Knee OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Knee Osteoarthritis

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

1 2

Inulin and Sodium Chloride

BBlue Earth Diagnostics

Phase 2

1 3

Surgicel

PPeking University Third Hospital

Medrol

1 5

Allocetra

EEnlivex Therapeutics Ltd.

Phase 2

1 6

Decadron

AAspen Global Incorporated

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 9

4p004

44Moving Biotech

Phase 2

1 10

Paracetamol

GSK

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Knee Osteoarthritis1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof of Concept Trial to Investigate the Efficacy and Safety of Intra-articular 4P004 in Subjects With Knee Synovitis and Osteoarthritis

Active, not recruiting·44Moving Biotech·Phase 2·NCT07225829·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 4p004. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 4p004. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — 4Moving Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: 44Moving Biotech

4p004

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Knee Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News